- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07942428
Enzymatic Treatment for Postoperative Nasal Fibrosis After Rhinoplasty
A Fixed-Sequence Crossover Clinical Trial Evaluating Enzymatic Treatment for Mild-to-Moderate Postoperative Nasal Fibrosis After Rhinoplasty
This single-arm, fixed-sequence clinical trial will evaluate an enzymatic preparation for mild-to-moderate postoperative fibrosis of the nasal soft-tissue envelope after rhinoplasty. Each participant will first receive 3 mL of sterile saline injected into the affected nasal area. Two weeks later, clinical assessment and high-resolution nasal ultrasonography, including elastography, will be performed, after which the participant will receive a 3-mL enzymatic preparation in the same affected area. A second clinical assessment and ultrasound examination will be performed 2 weeks after the enzymatic treatment. Changes during the saline and enzymatic treatment periods will be compared within each participant.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Adults with mild-to-moderate fibrosis of the nasal soft-tissue envelope after rhinoplasty will receive two interventions in a fixed sequence. During Period 1, 3 mL of sterile saline will be injected into the affected nasal area. At 2 weeks, clinical assessment and high-resolution nasal ultrasonography, including elastography, will be performed. The enzymatic preparation will then be injected into the same affected area. It will contain recombinant lipase, collagenase, and hyaluronidase and will be prepared by adding 1.5 mL of high-molecular-weight hyaluronic acid, waiting approximately 5 minutes, and then adding 1.5 mL of sterile saline, for a total volume of 3 mL. Two weeks after the enzymatic treatment, clinical assessment and ultrasound, including elastography, will be repeated. All participants will receive saline first and the enzymatic preparation second.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Minyor Avellaneda, MD, Plastic surgeon
- Telefonnummer: +57 (320) 767 4006
- E-Mail: contacto@nuarabelleza.com
Studienorte
-
-
Bogota D.C.
-
Bogotá, Bogota D.C., Kolumbien, 110121
- Rekrutierung
- NUARA
-
Kontakt:
- Minyor Avellaneda, MD, Plastic surgeon
- Telefonnummer: +57 (320) 767 4006
- E-Mail: contacto@nuarabelleza.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Adults aged 18 years or older. History of rhinoplasty performed at least 3 months before enrollment. Complete healing of the surgical wounds at enrollment. Mild-to-moderate fibrosis of the nasal soft-tissue envelope in an identifiable affected area, diagnosed by clinical examination and documented by baseline high-resolution nasal ultrasonography.
Ability and willingness to provide written informed consent. Ability and willingness to complete the study assessments and follow-up visits.
Exclusion Criteria:
- Severe nasal fibrosis or deformity requiring surgical correction or urgent treatment.
Active infection, open wound, ulceration, or tissue necrosis in the proposed injection area.
Previous injection or other treatment specifically for nasal fibrosis Known hypersensitivity to any component of the enzymatic preparation or to sterile saline.
Pregnancy or breastfeeding. Any medical condition that, in the investigator's judgment, makes study injections unsafe or prevents reliable completion of study assessments.
Inability to provide informed consent or comply with study procedures.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Fixed Sequence: Saline Followed by Enzymatic Treatment
All participants will first receive 3 mL of sterile saline injected into the affected nasal area. Two weeks later, after clinical assessment and ultrasound, they will receive 3 mL of a recombinant enzymatic preparation containing lipase, collagenase, and hyaluronidase, injected into the same affected area. The enzymatic preparation will be reconstituted with 1.5 mL of high-molecular-weight hyaluronic acid, followed approximately 5 minutes later by 1.5 mL of sterile saline. Final ultrasound and clinical assessment will be performed 2 weeks after the enzymatic treatment. |
A total volume of 3 mL of sterile saline injected into the affected nasal area once at the beginning of the study. A total volume of 3 mL containing recombinant lipase, collagenase, and hyaluronidase, injected into the affected nasal area 2 weeks after the saline injection. The preparation will be made by adding 1.5 mL of high-molecular-weight hyaluronic acid, waiting approximately 5 minutes, and then adding 1.5 mL of sterile saline. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Difference in change in nasal soft-tissue thickness between the saline and enzymatic treatment periods
Zeitfenster: Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
High-resolution nasal ultrasonography will be used to measure soft-tissue thickness at the prespecified affected area. Measurements will be obtained before saline treatment, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment. The change during the enzymatic period will be compared with the change during the saline period within each participant. Thickness will be recorded in millimeters. |
Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Difference in change in nasal soft-tissue elastography measurements between treatment
Zeitfenster: Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
Elastography will be recorded at the prespecified affected area at baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment. The change during the enzymatic period will be compared with the change during the saline period within each participant. The elastography parameter and units reported by the ultrasound system will be specified in the study protocol. |
Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
|
Change in structural characteristics of the nasal soft-tissue envelope
Zeitfenster: Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
Structural characteristics of the previously operated nasal soft-tissue envelope at the affected area will be assessed by high-resolution nasal ultrasonography at each study assessment. |
Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
|
Treatment-emergent adverse events
Zeitfenster: Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
Adverse events reported or observed after saline and enzymatic injections, including local pain, swelling, erythema, skin changes, infection, tissue injury, or other adverse events. |
Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Nascimento NS, Torres-Obreque KM, Oliveira CA, Rabelo J, Baby AR, Long PF, Young AR, Rangel-Yagui CO. Enzymes for dermatological use. Exp Dermatol. 2024 Jan;33(1):e15008. doi: 10.1111/exd.15008.
- Shekhter AB, Balakireva AV, Kuznetsova NV, Vukolova MN, Litvitsky PF, Zamyatnin AA Jr. Collagenolytic Enzymes and their Applications in Biomedicine. Curr Med Chem. 2019;26(3):487-505. doi: 10.2174/0929867324666171006124236.
- Menick FJ, Salibian A. Primary intranasal lining injury cause, deformities, and treatment plan. Plast Reconstr Surg. 2014 Nov;134(5):1045-1056. doi: 10.1097/PRS.0000000000000694.
- Kryczka J, Boncela J. Proteases Revisited: Roles and Therapeutic Implications in Fibrosis. Mediators Inflamm. 2017;2017:2570154. doi: 10.1155/2017/2570154. Epub 2017 May 31.
- Afratis NA, Klepfish M, Karamanos NK, Sagi I. The apparent competitive action of ECM proteases and cross-linking enzymes during fibrosis: Applications to drug discovery. Adv Drug Deliv Rev. 2018 Apr;129:4-15. doi: 10.1016/j.addr.2018.03.004. Epub 2018 Apr 5.
- Sharif-Askary B, Carlson AR, Van Noord MG, Marcus JR. Incidence of Postoperative Adverse Events after Rhinoplasty: A Systematic Review. Plast Reconstr Surg. 2020 Mar;145(3):669-684. doi: 10.1097/PRS.0000000000006561.
- Hacker S, Pollock J, Gubisch W, Haack S. Differences between Primary and Revision Rhinoplasty: Indications, Techniques, Grafts, and Outcomes. Plast Reconstr Surg. 2021 Sep 1;148(3):532-541. doi: 10.1097/PRS.0000000000008216.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 027
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
non considered in the patient informed consent
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .